Telomir Pharmaceuticals Inc TELO Q4 2025 Earnings WiderthanExpected Loss Highlights DevelopmentStage Challenges PENN Q1 2026 Earnings Steep EPS Miss Amid Operational Headwinds BSBR Q1 2023 Earnings Significant EPS Miss Amid Challenging Operating Environment ROP Q1 2026 Earnings EPS Surpasses Estimates Amid Operational Discipline VICR Q1 2026 Earnings EPS Surges Past Estimates with 1983 Surprise STSS Q3 2025 Earnings Losses Widen Sharply as Revenue Remains Absent